Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...
Investor's Business Daily on MSN
Nike beats Q2 views, but these factors drag shares lower
Nike CEO Elliott Hill said the Dow Jones giant is in the "middle innings of our comeback" after topping Q2 estimates.
Investor's Business Daily on MSN
Why FedEx stock is falling despite earnings surprise and price target hikes
The company remains in cost-cutting mode. On Thursday, FedEx said that its operating results improved in the second quarter, ...
The company is struggling to make ends meet as it loses a major undisclosed client.
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
24/7 Wall St. on MSN
Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback